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Abstract 
The  impact  of  chemotherapy  resistant  B
cells in multiple myeloma (MM) needs to be
evaluated by in vivo targeted therapy. Here we
report the conclusions from a phase II ran-
domized, placebo controlled trial adding flu-
darabine  to  the  induction  with  cyclophos-
phamide-dexamethasone.  Based on an inter-
im toxicity and safety analysis, the trial was
stopped following inclusion of 34 of a planned
80  patients  due  to  a  reduced  number  of
patients  (4/17)  actually  harvested  in  the
experimental arm compared to the control arm
(11/17; p<0.05). In conclusion, the scheduled
fludarabine dosage in 2 cycles combined with
alkylating therapy impairs stem cell mobiliza-
tion  and  standard  therapy  in  young  MM
patients and should not be administrated up-
front. 
Introduction
Due to a range of new drugs there has been
a  continuous  progress  in  the  treatment  of
multiple myeloma (MM). However, only a few
patients  are  considered  cured  so  far,  most
likely  due  to  the  nature  of  the  disease.
1-3
Recent data have indicated that the myeloma
cell  hierarchy  includes  resistant  circulating
clonal memory B cells, which differ consider-
ably from the classical end stage plasma cells,
infiltrating the bone marrow. The pathophysi-
ological  significance  of  these  cells  is
unknown, but hypothetically they may serve as
“sleeping” myeloma stem cells responsible for
and “feeding” post-treatment relapse and dis-
ease  progression.
4-5 The  clinical  impact  of
these cells needs to be evaluated by in vivo
targeted  therapy.  Therefore,  we  initiated  a
randomized phase II multicenter trial compar-
ing  induction  therapy  by  cyclophosphamide
plus dexamethasone with and without fludara-
bine, a DNA repair inhibitor. Fludarabine, 9-β-
D-arabinofuranosyl-2-fluoroadenine,  is  an
analog to adenosine cytotoxic against dividing
and resting cells.
6-7 In vivo, the combination of
a DNA damaging agent, e.g. adriamycine or
cyclophosphamide combined with fludarabine
is clinically active against B cells in CLL and
low-grade follicular lymphomas.
8-10 Although it
has been documented active against leukemia
and lymphoma, only recent data has suggested
efficacy in MM. In a previous open phase II
pilot study, we have documented that addition
of fludarabine to induction therapy is clinical-
ly feasible with only minor toxicity. A benefi-
cial clinical outcome was suggested including
a  reduction  of  minimal  residual  disease
(MRD) following the addition of fludarabine.
11
However, one concern during the trial design
discussion was the adverse impact of fludara-
bine  on  stem  cell  harvest  experienced  in
advanced CLL,
13 which, however, was not con-
sidered in untreated patient treatment.
The  main  objective  of  the  subsequent
NMSG n.13/03 phase II trial was to generate
data on toxicity, safety and efficacy by adding
fludarabine to standard induction therapy.
12 In
the close follow-up of the patient cohort it was
decided to perform an interim analysis, which
concluded that fludarabine in the experimen-
tal arm inhibits stem cell mobilization capaci-
ty and reduced the number of patients reach-
ing  high-dose  therapy  and  the  trial  was
stopped. Consequently, fludarabine in combi-
nation with alkylating agents should not be
administrated  as  up-front  therapy,  if  high-
dose therapy supported by autologous trans-
plantation is standard care.
Materials and Methods
Approval and patient eligibility
The scientific protocols were reviewed and
approved by the regional ethics committees in
Denmark  and  the  Danish  Drug  Agency
(Sagsnr. KA 03103 ms) and all patients gave
written informed consent before study entry.
All patients were over 18 years of age and were
referred  to  the  departments  for  diagnostic
evaluation.  Patients under 60 years of age who
had  Durie-Salmon  stage  I  with  at  least  one
bone lesion, II, or III myeloma were eligible.
The criteria for exclusion were prior treatment
for myeloma, another cancer, abnormal cardiac
function,  chronic  respiratory  disease,  abnor-
mal liver function or psychiatric disease.  
Trial design
This was a randomized, placebo controlled,
single blinded, phase II study evaluating toxi-
city  and  safety  of  fludarabine  added  to
cyclophosphamide  and  dexamethasone
(CyDex)  as  induction  therapy  in  younger
newly diagnosed symptomatic multiple myelo-
ma requiring therapy. The treatment regimen
CyDex as standard induction therapy was doc-
umented  in  NMSG  trial  n.11/01.
12 Patients
were  randomized  at  diagnosis  either  to
CyDex + placebo (control Arm A) or CyDex +
fludarabine (experimental Arm B). 
Treatment procedure
Fludarabine  was  considered  as  the  only
investigational  drug  in  this  study  adminis-
trated in induction phase I. 
Phase I
Arm A (conventional arm): CyDex + place-
bo, two (three) cycles in Phase I: two courses
of CyDex: cyclophosphamide 1000 mg/m
2 IV
day 1 and dexamethasone 40 mg/day PO on
day 1-4, and 9-12 + placebo PO; repeated once
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day  21.  The  third  cycle  of  CyDex  (without
placebo) was only given if the phase II treat-
ment could not be initiated within six weeks
after the start of CyDex II. Other steroids in
equipotent dose could be used instead of dex-
amethasone.
12
Arm B (experimental arm): CyDex plus flu-
darabine, two (three) cycles in Phase I: two
courses  of  CyDex:  cyclophosphamide  1000
mg/m
2 day 1 IV and dexamethasone 40 mg/d
(or other steroids in equipotent dose) PO on
days 1-4, and 9-12, combined with fludarabine
40  mg/m
2 PO  day  1-3  each  cycle;  repeated
once day 21. The third cycle of CyDex (with-
out fludarabine) was only given if the phase II
treatment  could  not  be  initiated  within  six
weeks after the start of the second CyDex plus
fludarabine course.  
Common trunk (phases II–IV)
This was as described in previous reports
from  NMSG.
3,12 In  brief,  the  priming  and
apheresis  phase  II  included  cyclophos-
phamide 2 g/m
2 given as a single dose intra-
venously  during  60  minutes.  Uroprotection
with  Mesna  160%  of  the  cyclophosphamide
dose divided in four doses (before 3, 6 and 9
h after start of cyclophosphamide) and diure-
sis of at least 2.5 L/m
2 the following 24 hours.
Granulocyte  colony-stimulating  factor  (G-
CSF)  was  initiated  day  4  after  cyclophos-
phamide  as  Neupo-gen
® 5-10  ug/kg  daily
adjusted to appropriate vial size. Peripheral
blood stem cell leukapheresis were performed
during  mobilization,  guided  by  CD34  blood
levels,  by  harvest  of  a  minimum  of  2ￗ10
6
CD34
+ cells per kilogram body weight.
Following harvest of a sufficient graft, the
patients passed to phase III: high-dose thera-
py with melphalan 200 mg/m
2 given as a sin-
gle dose intravenously, followed by stem cell
infusion 48 hours later, and G-CSF (Neupo-
gen
® 5 µg/kg daily or Neulasta
® 12 mg) one
injection  from  day  4  after  graft  reinfusion,
until the absolute neutrophil count is more
than 1.0ￗ10
9/L for three consecutive days.
The patients were followed as outpatients
during phase IV.
Statistical analysis 
The  proportions  of  patients  with  a  given
characteristic were compared using Fisher’s
exact test for binary data. The distributions of
continuous quantities were examined to con-
trol that they followed Gaussian distributions
with good approximation using Kolmogorow-
Smirnow's test supplemented by Q-Q plots. 
If  they  did,  either  directly  or  following
transformation (square root or logarithmic),
the mean values of the two groups were com-
pared  using  a  t-test.  If  not  the  two  groups
were compared using Mann Whitney's test.
Results and Discussion
Treatment cycles given during
induction phase I
All  patients  in  the  conventional  arm
received  the  scheduled  cycles  of  therapy.
However,  in  the  experimental  arm  this  was
only the case for 11/17 patients as 6 patients
were stopped before or following the first cycle
of therapy (Table 1). Three of these patients
did not start therapy, suggesting bias from the
clinician, for whom the therapy arm was not
blinded. Such a bias may be the result from the
relative  intensive  dosage  of  fludarabine
administrated in this trial of 40 mg/m
2 PO for
three days in each of two cycles, compared to
our previous trial
2 where we administered a
dose of 25 mg/m
2 intravenously for five days.
Following discussions within NMSG the proto-
col  group  selected  oral  administration  over
three days attempting to reach an equivalent
total dose of fludarabine as used previously.
Our  previous  experience
2 administrating  a
total dosage of 125 mg/m
2 fludarabine over five
days was moderate neutropenia, no thrombo-
cytopenia  or  severe  infectious  episodes.  We
observed  all  9  of  the  fludarabine-treated
patients responding to treatment with 2 com-
plete  remissions  and  7  partial  remissions,
compared to 5 responders (all PR) in the con-
trol-arm. Furthermore, the effect on the blood
circulating myeloma compartments identified
a significant reduction of CD19
+ B cells and
myeloma plasma cells in the fludarabine-arm,
concluding  that  fludarabine  therapy  in  MM
was feasible with a potential clinical efficacy.
However, in the current trial, unexpected side
effects  were  initially  observed  which  may
explain the drop-out of the 6 patients (Table 1)
before the end of induction therapy.  
Toxicity and adverse events follow-
ing induction phase I
In accordance with the CTC criteria, no dif-
ference in severe toxicity was found. However,
analysis of laboratory quantities following the
second treatment showed a borderline reduc-
tion of blood lymphocytes from mean 1.12 (SD
0.4)  to  0.73  (SD  0.6;  p=0.055)  and  an
increased plasma creatinine level from mean
57.8  (SD  14.2)  to  mean  124.2  (SD  28.8;
p=0.035).  All  other  variables  registered
showed no difference including performance
score. Many clinical trials in CLL have shown
the combination of fludarabine and cyclophos-
phamide to have tolerable toxicity,
13-15 however,
the  observed  significant  reduction  in  renal
function may be due to latent myeloma specif-
ic  kidney  impairment.  All  serious  adverse
events were reported to The Trial Secretariat
within one working day of discovery or notifi-
cation  of  the  event.  Initial  serious  adverse
event information and all amendments or addi-
Article
Table 1. Number of treatment cycles during induction therapy (phase I).
Variable Placebo (n) % Intervention (n) % p
No treatment (0) 0.0 (3) 17.6 0.054
(Mann Whitney test)
1 treatment  (0) 0.0 (3) 17.6
2 treatments (15) 88.2 (9) 52.9
3 treatments (2) 11.8 (2) 11.8
Table 2. Fraction of patients subjected to harvest of an autograft (phase II).
Variable Placebo (n) % Intervention (n) % p
Number of patients subjected (11) 64.7 % (4) 23.5 % 0.037
to at least one harvest  
Mean total harvest of CD34
+ (11) 736±465 (4) 416±248 0.12
cells ￗ10
6 ± SD
Mean average number of CD34
+ (11) 584±501 (4) 251.2 (152.6) 0.071
cells ￗ10
6 per harvest ± SD
Number of apheresis to collect  Placebo (n) Intervention (n)  p
>5ￗ10
6 CD 34
+ cells/kg
No harvest session/mobilization failure  (6) 35.3% (13) 76.5% 0.11
1 harvest session  (7) 41.2% (02) 11.8%
2 harvest sessions  (2) 11.8% (01) 05.9%
3 harvest sessions  (2) 11.8% (01) 05.9%[page 64] [Hematology Reviews 2009; 1:e11]
tions  were  recorded  on  the  Adverse  Event
Form. This was reviewed and documented that
CMV-reactivating was seen in one patient in
the standard arm and 3 patients in the experi-
mental arm. 
Priming for stem cell mobilization
and harvest during phase II
Fifteen of 17 patients and 12/17 were primed
with standard care cyclophosphamide and rhG-
CSF in arms A and B, respectively. Successful
mobilization to reach the level of >10 CD34
+
cells per microliter blood triggered leukaphere-
sis and was obtained in 11/17 patients in arm
A but only in 4/17 patients in arm B (Table 2).
This difference was significant at the interim
analysis performed by an independent group of
experts and the decision was taken to stop the
trial.  Comparison  of  the  total  and  average
number of CD34
+ cells harvested did not reveal
differences  in  patients  actually  undergoing
apheresis. The situation concerning published
data about the adverse impact of fludarabine
on stem cell harvest is now clearer. In a survey
of  advanced  CLL  from  122  centers  of  the
European  Group  of  Blood  and  Marrow
Transplantation (EBMT), it was concluded that
attention  should  be  given  to  the  timing  of
mobilization with respect to the last dose of
fludarabine.
13 This has been further supported
by a study of B-CLL after front-line treatment
with  fludarabine  (30  mg/m
2 per  day)  and
cyclophosphamide (200 mg/m
2 per day) both
given  orally  for  five  consecutive  days  in  six
monthly  courses.  After  evaluation  performed
two months after the last course, responding
patients were considered for PBPC collection.
Following conventional rhG-CSF, priming until
adequate blood CD34 circulation was achieved
and a harvest procedure was initiated success-
fully in only 12 of the 32 CLL patients.
14
The present report supports this observation
and further adds to our knowledge that as few
as one to two series of fludarabine may result
in poor mobilization and impair standard ther-
apy. Recently, the stem cell toxicity has been
supported by the observation that the risk for
sMDS/AML was correlated to the use of flu-
darabine based on an unknown mechanism.
15
Response evaluation following
phase II
Response  evaluation  performed  following
phase I-II prior to high-dose therapy revealed
7/13 and 5/7 patients obtained a partial remis-
sion. The trend towards more patients achiev-
ing CR in the intervention arm observed in our
previous phase II study could not be confirmed
in this trial (results not shown). There was no
difference in graft quality, evaluated by time to
neutrophil and platelet recovery. One patient
died from treatment complication in the exper-
imental  arm  due  to  protocol  violation:  the
patient  had  impaired  renal  function  and
received a full dose of fludarabine. This was
reported  and  reviewed  by  the  Danish  Drug
Agency. Follow-up in December 2008 revealed
that 12/13 and 9/13 patients had responded to
therapy with 4/13 and 3/13 obtaining CR at any
time during follow-up. The number of patients
dying from complications or progressive dis-
ease was 2/17 and 5/16, respectively, with no
significant difference between the two arms.
Conclusions
In  conclusion,  the  scheduled  fludarabine
dosage in two cycles combined with alkylating
therapy  impairs  stem  cell  mobilization  and
standard therapy in young MM patients and
should  not  be  administrated  up-front.  This
observation is in accordance with recent data
from up-front therapy in CLL. 
We are now left with the challenge of under-
standing  the  mechanisms  of  fludarabine
responsible  for  the  negative  side  effect  on
mobilization of normal hematopoietic progeni-
tors, as well as the potential therapeutic effect
on marrow and blood B cells in MM and other
B-cell malignancies. This is of special interest
as the myeloma cell hierarchy includes resist-
ant circulating clonal memory B cells, which
differ considerably from the classical end stage
plasma cells, infiltrating the bone marrow. The
pathophysiological significance of these cells
is at present unknown, but hypothetically they
may serve as “sleeping” myeloma stem cells
responsible for and “feeding” post-treatment
relapse and disease progression,
4-5 as studied
by the Myeloma Stem Cell Network supported
by the 6
th FP from the EU.
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